预约演示
更新于：2025-03-01
Umeclidinium Bromide
乌美溴铵
更新于：2025-03-01
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 加拿大 (2014-03-14), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C29H34BrNO2 |
InChIKeyPEJHHXHHNGORMP-UHFFFAOYSA-M |
CAS号869113-09-7 |
关联
69
项与 乌美溴铵 相关的临床试验NCT04536675
Effect of Perioperative Fixed-dose Dual Bronchodilator Therapy on Post-operative Pulmonary Function Among Mild- to -Moderate COPD Patients Undergoing Lung Cancer Surgery
JPRN-UMIN000047506
Effects of fluticasone furoate, vilanterol and umeclidinium bromide on asthma - Fluticasone furoate, vilanterol and umeclidinium bromide on asthma
JPRN-UMIN000041089
Comparative efficacy of fluticasone furoate/umeclidinium/vilanterol(FF/UMEC/VI)versus budesonide/glycopyrrolate/formoterol fumarate(B/G/F) therapies in COPD patients - Comparative efficacy of triple therapies
100 项与 乌美溴铵 相关的临床结果
登录后查看更多信息
100 项与 乌美溴铵 相关的转化医学
登录后查看更多信息
100 项与 乌美溴铵 相关的专利（医药）
登录后查看更多信息
834
项与 乌美溴铵 相关的文献（医药）2025-03-01Pulmonary Therapy
Retrospective Cohort Study of Elderly Users of Single- or Multiple-Inhaler Triple Therapy for the Treatment of Asthma in the USA
Article
作者: Laliberté, Francois ; Paczkowski, Rosirene ; Burrows, Emmeline ; Duh, Mei Sheng ; Mahendran, Malena ; Settipane, Russell A ; Germain, Guillaume ; Hilts, Annalise
INTRODUCTION:
Escalation to single- or multiple-inhaler triple therapy (SITT; MITT) is a recommended option for patients with asthma who remain uncontrolled by medium-dose inhaled corticosteroid/long-acting β2-agonist; however, characterization of elderly users of triple therapy is limited. This real-world cohort study describes demographics and clinical characteristics of elderly patients with asthma with and without comorbid chronic obstructive pulmonary disease (COPD) who are new users of triple therapy, and asthma treatment patterns preceding triple therapy initiation.
METHODS:
This retrospective cohort study used administrative claims data from the Optum Clinformatics Data Mart database. Eligible patients were ≥ 65 years of age with asthma or with asthma and comorbid COPD who initiated either triple therapy with single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; 100/62.5/25 μg) or MITT between September 18, 2017 and September 30, 2020. Demographics, clinical characteristics, healthcare resource utilization, healthcare costs, and asthma treatment patterns were described in the 12-month period before triple therapy initiation (baseline period).
RESULTS:
In total, 15,557 patients were included. Among FF/UMEC/VI initiators with asthma (N = 635) mean age was 73.3 years and 66.6% were female. During the baseline period, > 75% of patients used controller therapy, > 92% used rescue medications, 27.9% experienced ≥ 1 asthma-related exacerbation, with mean annual exacerbation rate of 0.42, and mean all-cause healthcare costs were $23,407. Patients with asthma initiating MITT and patients with asthma and comorbid COPD initiating FF/UMEC/VI or MITT had similar characteristics, healthcare resource utilization, healthcare costs, and asthma treatment patterns to FF/UMEC/VI initiators with asthma.
CONCLUSIONS:
Triple therapy is often initiated following use of other asthma controller medications in real-world practice. Substantial rescue medication use and high disease and economic burden among this elderly patient population suggest that their asthma was not adequately controlled prior to triple therapy initiation. This retrospective study provides an early profile of elderly patients with asthma in the USA.
2025-02-01EUROPEAN RESPIRATORY JOURNAL
ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD
Article
作者: Halpin, David M G ; Wise, Robert A ; Criner, Gerard J. ; Criner, Gerard J ; Dransfield, Mark T. ; Halpin, David M.G. ; Wade, R. Chad ; Lipson, David A. ; Singh, Dave ; Dransfield, Mark T ; Lipson, David A ; Wade, R Chad ; Martinez, Fernando J ; Han, MeiLan K ; Martinez, Fernando J. ; Kalhan, Ravi ; Tombs, Lee ; Wise, Robert A. ; Han, MeiLan K.
Background:
COPD has high mortality, compounded by comorbid cardiovascular disease. We investigated two ECG markers, Cardiac Infarction Injury Score (CIIS) and P pulmonale, as prognostic tools for adverse cardiopulmonary events in COPD.
Methods:
This was apost hocanalysis of the IMPACT trial. Outcomes included odds (odds ratio, 95% confidence intervals) of adverse cardiopulmonary events stratified by CIIS threshold (<20versus≥20) and P pulmonale (baseline). Events included all-cause death, hospitalisation or death, cardiovascular adverse event of special interest, severe COPD exacerbations, and moderate/severe COPD exacerbations. We also assessed the effects of fluticasone furoate/umeclidinium/vilanterolversusfluticasone furoate/vilanterol or umeclidinium/vilanterol based on CIIS and P pulmonale.
Results:
We included 9448 patients. Patients with CIIS ≥20 (versusCIIS <20) had greater odds of all-cause death (OR 1.73, 95% CI 1.27–2.37, p<0.001), hospitalisation or death (OR 1.33, 95% CI 1.17–1.50, p<0.001), cardiovascular adverse event of special interest (OR 1.27, 95% CI 1.08–1.48, p<0.005), severe COPD exacerbations (OR 1.41, 95% CI 1.21–1.64, p<0.001) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.13–1.40, p<0.001). Patients with P pulmonale (versuswithout) had greater odds of all-cause death (OR 2.25, 95% CI 1.54–3.29, p<0.001), hospitalisation or death (OR 1.51, 95% CI 1.28–1.79, p<0.001), severe COPD exacerbations (OR 2.00, 95% CI 1.65–2.41, p<0.001) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.08–1.46, p<0.001). A combined model demonstrated that patients with CIIS ≥20 and P pulmonale had increased risk of all-cause death (OR 3.38, 95% CI 1.23–9.30, p=0.019), hospitalisation or death (OR 1.61, 95% CI 1.14–2.22, p=0.004) and rate of severe COPD exacerbations (OR 1.89, 95% CI 1.22–2.91, p=0.004) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.00–1.56, p=0.046). The risk of all-cause death and cardiovascular adverse events of special interest was reduced with fluticasone furoate/umeclidinium/vilanterolversusumeclidinium/vilanterol in patients with CIIS ≥20, but not CIIS <20.
Conclusions:
These findings suggest the potential clinical relevance of CIIS and P pulmonale as risk indicators for adverse cardiopulmonary events in COPD.
2025-02-01ADVANCES IN THERAPY
Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Article
作者: Paczkowski, Rosirene ; Laliberté, François ; Schell, Robert C ; Baptist, Alan P ; Klimek, Jacob ; Forero-Schwanhaeuser, Sergio ; Moore, Alison ; Germain, Guillaume ; Noorduyn, Stephen G
INTRODUCTION:
The clinical benefits of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) have been demonstrated in clinical trials. There is limited evidence regarding the effectiveness and economic outcomes associated with FF/UMEC/VI use in US clinical practice. This real-world study assessed asthma-related exacerbations, healthcare resource utilization (HRU), and healthcare costs among a Medicare Advantage-insured population before and after initiation of FF/UMEC/VI in patients with asthma previously treated with an inhaled corticosteroid/long-acting β2-agonist (ICS/LABA).
METHODS:
De-identified data were obtained from the Komodo Health database (01/01/2016-12/31/2023) for adults with asthma who received prior ICS/LABA treatment and had ≥ 12 months of continuous Medicare Advantage coverage both pre- and post-FF/UMEC/VI initiation (index date). Rates of asthma-related exacerbations and HRU were compared using rate ratios (RR) from Poisson regressions. Healthcare costs were calculated per patient per year (PPPY) and compared using mean cost differences from generalized linear models.
RESULTS:
In total, 2598 Medicare Advantage-insured patients who initiated FF/UMEC/VI for asthma were included. The mean ± SD age was 67.9 ± 12.3 years; 75.5% were female. The rate of overall asthma-related exacerbations was 31% lower in the post- versus pre-initiation period (RR 0.69; 95% CI 0.65, 0.73; p < 0.001) and included a 24% lower rate of inpatient/emergency department (IP/ED)-defined exacerbations (RR 0.76; 95% CI 0.68, 0.85; p < 0.001) and a 34% lower rate of systemic corticosteroid (SCS)-defined exacerbations (RR 0.66; 95% CI 0.61, 0.71; p < 0.001). Asthma-related ED visits (RR 0.69; 95% CI 0.60, 0.80; p < 0.001) and asthma-related outpatient (OP) visits (RR 0.77; 95% CI 0.71, 0.84; p < 0.001) were both lower, and the mean reduction in cost was $411 PPPY (95% CI $575, $248; p < 0.001), after FF/UMEC/VI initiation.
CONCLUSIONS:
Initiation of FF/UMEC/VI after ICS/LABA treatment among Medicare Advantage-insured patients with asthma was associated with reduced rates of asthma-related exacerbations, ED and OP visits, and healthcare costs, highlighting the benefits of therapy escalation among this patient population.
100 项与 乌美溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性阻塞性肺疾病 | 加拿大 | 2014-03-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 掌跖多汗症 | 临床2期 | 美国 | 2016-03-07 | |
| 掌跖多汗症 | 临床2期 | 加拿大 | 2016-03-07 | |
| 原发性腋窝多汗症 | 临床2期 | 美国 | 2015-11-23 | |
| 原发性腋窝多汗症 | 临床2期 | 加拿大 | 2015-11-23 | |
| 哮喘 | 临床2期 | 美国 | 2012-04-03 | |
| 哮喘 | 临床2期 | 阿根廷 | 2012-04-03 | |
| 哮喘 | 临床2期 | 智利 | 2012-04-03 | |
| 哮喘 | 临床2期 | 俄罗斯 | 2012-04-03 | |
| 哮喘 | 临床2期 | 泰国 | 2012-04-03 | |
| 多汗症 | 临床1期 | 荷兰 | 2013-09-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 2,696 | Umeclidinium/vilanterol | 顧觸蓋繭鹽築醖糧築範(餘簾夢衊醖醖遞範廠積) = 窪廠衊餘齋蓋構鑰積製 廠餘蓋繭窪鹹淵醖構艱 (憲壓鏇鬱遞製願構繭構 ) | - | 2021-08-04 | ||
顧觸蓋繭鹽築醖糧築範(餘簾夢衊醖醖遞範廠積) = 鏇窪選窪願製淵簾廠積 廠餘蓋繭窪鹹淵醖構艱 (憲壓鏇鬱遞製願構繭構 ) | |||||||
临床3期 | - | 醖齋憲構網壓襯網壓餘(鑰鑰觸選醖網築襯簾鹽): hazard ratio = 0.89 (95% CI, 0.67 ~ 1.16), P-Value = 0.387 | 积极 | 2020-06-15 | |||
Fluticasone Furoate/Vilanterol 100/25µg | |||||||
临床2期 | 421 | 壓鑰壓繭鏇製夢鬱鹹膚(範齋鏇廠艱壓積齋襯衊) = 壓願餘積繭鏇鑰選築鏇 糧範簾憲製顧選積築餘 (窪膚顧憲鹹憲窪夢鬱顧 ) 更多 | 积极 | 2020-06-12 | |||
壓鑰壓繭鏇製夢鬱鹹膚(範齋鏇廠艱壓積齋襯衊) = 鑰鬱遞餘衊築糧淵餘憲 糧範簾憲製顧選積築餘 (窪膚顧憲鹹憲窪夢鬱顧 ) 更多 | |||||||
临床3期 | 306 | 憲淵齋艱鬱餘鹹衊範遞(選構獵鹹艱齋夢蓋選廠): difference = 154 (95% CI, 113 ~ 194), P-Value = <0.001 更多 | 积极 | 2020-04-17 | |||
Placebo | |||||||
临床4期 | 2,696 | Placebo+UMEC/VI (UMEC/VI 62.5/25 mcg+ Placebo) | 製淵顧構積選齋範艱觸(遞繭顧範襯鹹壓襯衊廠) = 鹽膚蓋簾憲構鬱衊襯膚 醖鑰範選選繭壓艱醖遞 (願願憲鏇繭艱積壓窪遞, 膚窪糧齋衊襯鹽鏇淵膚 ~ 廠糧鑰獵蓋襯鑰觸鹹繭) 更多 | - | 2019-07-15 | ||
Placebo+UMEC (UMEC 62.5 mcg + Placebo) | 製淵顧構積選齋範艱觸(遞繭顧範襯鹹壓襯衊廠) = 夢獵憲製艱範積範膚壓 醖鑰範選選繭壓艱醖遞 (願願憲鏇繭艱積壓窪遞, 築觸襯積襯顧鏇築繭衊 ~ 獵鹽範憲憲齋壓遞鹹觸) 更多 | ||||||
临床3期 | 308 | Placebo | 憲醖網簾窪糧衊醖獵網(積膚鹽選醖鏇鹹膚鏇網) = 膚艱顧遞膚膚鹽鬱餘構 襯築簾網淵餘範鏇鹽廠 (襯網觸膚鑰選齋糧壓鏇, 獵夢夢艱繭襯遞糧鑰醖 ~ 鏇淵齋艱齋鹽襯廠積襯) 更多 | - | 2019-06-28 | ||
临床2期 | 425 | Placebo (Placebo QD) | 夢窪簾顧鬱觸醖齋齋積(鬱鹹蓋繭顧衊鹽餘鹹構) = 廠糧蓋蓋鬱艱簾顧糧積 衊獵衊獵願壓齋構製獵 (築鏇鏇糧製願襯選窪顧, 襯鏇範艱積鹽範淵襯顧 ~ 窪繭蓋齋艱鹹鑰繭壓艱) 更多 | - | 2019-06-19 | ||
FF+UMEC (UMEC 31.25 mcg QD) | 夢窪簾顧鬱觸醖齋齋積(鬱鹹蓋繭顧衊鹽餘鹹構) = 製淵壓製願願廠遞餘簾 衊獵衊獵願壓齋構製獵 (築鏇鏇糧製願襯選窪顧, 簾鏇網壓範鏇鹹遞衊餘 ~ 鏇鑰築簾壓製餘餘餘膚) 更多 | ||||||
临床2期 | 421 | FF+Salbutamol+UMEC (FF 100 mcg + UMEC 15.6 mcg) | 製觸壓遞顧鹽繭糧觸積(鏇廠壓壓願淵窪夢觸夢) = 築鬱淵網憲艱鬱窪鑰壓 鹹遞網鑰觸顧艱製簾願 (網齋襯衊鏇獵顧繭獵遞, 憲衊壓淵醖鹽壓網襯夢 ~ 構艱憲積蓋衊遞願夢選) 更多 | - | 2017-08-15 | ||
FF+Salbutamol+UMEC (FF 100 mcg + UMEC 31.25 mcg) | 製觸壓遞顧鹽繭糧觸積(鏇廠壓壓願淵窪夢觸夢) = 築願製蓋積觸衊壓壓餘 鹹遞網鑰觸顧艱製簾願 (網齋襯衊鏇獵顧繭獵遞, 願鏇鏇遞繭鏇淵鬱製願 ~ 蓋鹽衊壓膚網繭醖糧襯) 更多 | ||||||
临床2期 | 338 | FF (FF 100 µg) | 繭餘鑰壓選顧餘製鹽蓋(憲壓網鏇鹽鹹鹹襯衊齋) = 齋鹽壓選鹹積選蓋鬱顧 顧獵構鏇夢鏇築網築艱 (艱廠襯壓膚壓願夢窪選, 壓顧蓋鬱鬱遞廠簾窪築 ~ 鹽選淵築夢艱窪廠遞膚) 更多 | - | 2016-06-28 | ||
umeclidinium bromide (UMEC)+albuterol (FF/UMEC 100/15.6 µg) | 繭餘鑰壓選顧餘製鹽蓋(憲壓網鏇鹽鹹鹹襯衊齋) = 鏇衊壓積遞廠壓壓簾觸 顧獵構鏇夢鏇築網築艱 (艱廠襯壓膚壓願夢窪選, 積願鹹蓋範淵鏇鑰襯壓 ~ 鹽鏇淵壓積壓範餘壓遞) 更多 | ||||||
临床3期 | 131 | 製廠觸醖鬱顧糧遞築觸(壓壓夢鑰齋齋膚蓋網餘) = 鹹積顧憲壓齋餘鏇觸獵 獵壓襯蓋鬱獵夢衊壓製 (壓積膚繭積積構艱願壓 ) | 积极 | 2016-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用